CYP1A2 rs762551 polymorphism contributes to cancer susceptibility: A meta-analysis from 19 case-control studies

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Wang, Hongge ^a   Zhang, Zhi ^b   Han, Sugui ^c   Lu, Yujuan ^b   Feng, Fumin ^a   Yuan, Juxiang ^a  

^a HEBEI UNITED UNIVERSITY   (China)

^b TANGSHAN GONGREN HOSPITAL   (China)

^c Department of Clinical laboratory   (China)

Author keywords

Cancer; CYP1A2; Meta analysis; Polymorphism

Indexed keywords

CYTOCHROME P450 1A2;

ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CAUCASIAN; COLORECTAL CANCER; CYTOCHROME P450 1A2 GENE; ETHNICITY; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LUNG CANCER; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A2; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NEOPLASMS; RISK;

EID: 84869102698     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-528     Document Type: Article

References (50)

1. Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet 2010, 127(1):1-17. 10.1007/s00439-009-0748-0, 19823875.
2. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 1995, 5(5):259-274. 10.1097/00008571-199510000-00001, 8563766.
3. Landi MT, Sinha R, Lang NP, Kadlubar FF. Human cytochrome P4501A2. IARC Sci Publ 1999, 148:173-195.
4. Jorge-Nebert LF, Jiang Z, Chakraborty R, Watson J, Jin L, McGarvey ST, Deka R, Nebert DW. Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations. Hum Mutat 2010, 31(1):27-40. 10.1002/humu.21132, 2797837, 19802894.
5. Aitchison KJ, Gonzalez FJ, Quattrochi LC, Sapone A, Zhao JH, Zaher H, Elizondo G, Bryant C, Munro J, Collier DA, et al. Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics 2000, 10(8):695-704. 10.1097/00008571-200011000-00004, 11186132.
6. Sterling KM, Cutroneo KR. Constitutive and inducible expression of cytochromes P4501A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells. J Cell Biochem 2004, 91(2):423-429. 10.1002/jcb.10753, 14743400.
7. Khvostova EP, Pustylnyak VO, Gulyaeva LF. Genetic Polymorphism of Estrogen Metabolizing Enzymes in Siberian Women with Breast Cancer. Genet Test Mol Biomarkers 2012, 16(3):167-173. 10.1089/gtmb.2011.0131, 21977969.
8. Singh AP, Pant MC, Ruwali M, Shah PP, Prasad R, Mathur N, Parmar D. Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark 2010, 8(6):351-359.
9. B'Chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S. CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci 2009, 84(21-22):779-784.
10. Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 2007, 28(6):1287-1293. 10.1093/carcin/bgm021, 17259654.
11. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, Navarro M, de Oca J, Capella G, Canzian F. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 2005, 15(8):535-546. 10.1097/01.fpc.0000165904.48994.3d, 16006997.
12. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999, 125(4):803-808. 10.1093/oxfordjournals.jbchem.a022352, 10101295.
13. Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo MG, Zengil H, Dahl ML. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 2009, 10(5):769-778. 10.2217/pgs.09.22, 19450128.
14. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007, 63(6):537-546. 10.1007/s00228-007-0288-2, 17370067.
15. Wang H, Yamamoto JF, Caberto C, Saltzman B, Decker R, Vogt TM, Yokochi L, Chanock S, Wilkens LR, Le Marchand L. Genetic variation in the bioactivation pathway for polycyclic hydrocarbons and heterocyclic amines in relation to risk of colorectal neoplasia. Carcinogenesis 2010, 32(2):203-209. 3026844, 21081473.
16. Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, Khuhaprema T, Brennan P, Boffetta P, Yoshida T. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer 2009, 125(4):837-843. 10.1002/ijc.24434, 19415745.
17. Kobayashi M, Otani T, Iwasaki M, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Sakamoto H, Yoshida T, Tsugane S. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan. Gastric Cancer 2009, 12(4):198-205. 10.1007/s10120-009-0523-x, 20047124.
18. Osawa Y, Osawa KK, Miyaishi A, Higuchi M, Tsutou A, Matsumura S, Tabuchi Y, Tsubota N, Takahashi J. NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev 2007, 8(1):103-108.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188. 10.1016/0197-2456(86)90046-2, 3802833.
20. Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol 2009, 62(Pt 1):97-128.
21. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Stat Med 1995, 14(4):395-411. 10.1002/sim.4780140406, 7746979.
22. Hysong SJ. Meta-analysis: audit and feedback features impact effectiveness on care quality. Med Care 2009, 47(3):356-363. 10.1097/MLR.0b013e3181893f6b, 19194332.
23. Biljana M, Jelena M, Branislav J, Milorad R. Bias in meta-analysis and funnel plot asymmetry. Stud Health Technol Inform 1999, 68:323-328.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
25. Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 2004, 5(3):211-224. 10.2174/1389200043335621, 15180491.
26. Han XM, Zhou HH. Polymorphism of CYP450 and cancer susceptibility. Acta Pharmacol Sin 2000, 21(8):673-679.
27. Jernstrom H, Henningson M, Johansson U, Olsson H. Coffee intake and CYP1A2*1F genotype predict breast volume in young women: implications for breast cancer. Br J Cancer 2008, 99(9):1534-1538. 10.1038/sj.bjc.6604687, 2579678, 18813311.
28. Tsukino H, Kuroda Y, Nakao H, Imai H, Inatomi H, Osada Y, Katoh T. Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol 2004, 130(2):99-106. 10.1007/s00432-003-0512-0, 14648207.
29. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham NJ. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003, 55(1):68-76. 10.1046/j.1365-2125.2003.01733.x, 1884179, 12534642.
30. Kiss I, Orsos Z, Gombos K, Bogner B, Csejtei A, Tibold A, Varga Z, Pazsit E, Magda I, Zolyomi A, et al. Association between allelic polymorphisms of metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1, mEH) and occurrence of colorectal cancer in Hungary. Anticancer Res 2007, 27(4C):2931-2937.
31. MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat 2010, 119(2):463-474. MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk.
32. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol 2009, 41(2):259-266. 10.1007/s11255-008-9444-6, 18690546.
33. Aldrich MC, Selvin S, Hansen HM, Barcellos LF, Wrensch MR, Sison JD, Kelsey KT, Buffler PA, Quesenberry CP, Seldin MF, et al. CYP1A1/2 haplotypes and lung cancer and assessment of confounding by population stratification. Cancer Res 2009, 69(6):2340-2348. 10.1158/0008-5472.CAN-08-2576, 3018237, 19276377.
34. Suzuki H, Morris JS, Li Y, Doll MA, Hein DW, Liu J, Jiao L, Hassan MM, Day RS, Bondy ML, et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 2008, 29(6):1184-1191. 10.1093/carcin/bgn085, 2443278,2443278, 18499698.
35. Saebo M, Skjelbred CF, Brekke Li K, Bowitz Lothe IM, Hagen PC, Johnsen E, Tveit KM, Kure EH. CYP1A2 164 A-->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas. Anticancer Res 2008, 28(4C):2289-2295.
36. Yoshida K, Osawa K, Kasahara M, Miyaishi A, Nakanishi K, Hayamizu S, Osawa Y, Tsutou A, Tabuchi Y, Shimada E, et al. Association of CYP1A1, CYP1A2, GSTM1 and NAT2 gene polymorphisms with colorectal cancer and smoking. Asian Pac J Cancer Prev 2007, 8(3):438-444.
37. Kotsopoulos J, Ghadirian P, El-Sohemy A, Lynch HT, Snyder C, Daly M, Domchek S, Randall S, Karlan B, Zhang P, et al. The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev 2007, 16(5):912-916. 10.1158/1055-9965.EPI-06-1074, 17507615.
38. Long JR, Egan KM, Dunning L, Shu XO, Cai Q, Cai H, Dai Q, Holtzman J, Gao YT, Zheng W. Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Pharmacogenet Genomics 2006, 16(4):237-243. 10.1097/01.fpc.0000189803.34339.ed, 16538170.
39. Li D, Jiao L, Li Y, Doll MA, Hein DW, Bondy ML, Evans DB, Wolff RA, Lenzi R, Pisters PW, et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 2006, 27(1):103-111. 1350610, 15987714.
40. Bae SY, Choi SK, Kim KR, Park CS, Lee SK, Roh HK, Shin DW, Pie JE, Woo ZH, Kang JH. Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci 2006, 97(8):774-779. 10.1111/j.1349-7006.2006.00241.x, 16800822.
41. Goodman MT, Tung KH, McDuffie K, Wilkens LR, Donlon TA. Association of caffeine intake and CYP1A2 genotype with ovarian cancer. Nutr Cancer 2003, 46(1):23-29. 10.1207/S15327914NC4601_03, 12925300.
42. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558. 10.1002/sim.1186, 12111919.
43. Smith E. Uncertainty analysis. Encyclopedia of Environmetrics. volume 4 2002, 2283-2297. Wiley, Chichester, EI-Shaarawi AH, Piegorsch WW.
44. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996, 273(5281):1516-1517. 10.1126/science.273.5281.1516, 8801636.
45. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003, 33(2):177-182. 10.1038/ng1071, 12524541.
46. Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet 2004, 20(9):439-444. 10.1016/j.tig.2004.06.014, 15313553.
47. Tao L, Xiang YB, Chan KK, Wang R, Gao YT, Yu MC, Yuan JM. Cytochrome P4501A2 phenotype and bladder cancer risk: the Shanghai bladder cancer study. Int J Cancer 2011, 130(5):1174-1183.
48. Chen X, Wang L, Zhi L, Zhou G, Wang H, Zhang X, Hao B, Zhu Y, Cheng Z, He F. The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin Pharmacol Ther 2005, 78(3):249-259. 10.1016/j.clpt.2005.05.012, 16153396.
49. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999, 47(4):445-449. 2014233, 10233211.
50. Gilliland FD. Ethnic differences in cancer incidence: a marker for inherited susceptibility?. Environ Health Perspect 1997, 105(Suppl 4):897-900. 10.1289/ehp.97105s4897, 1470049, 9255577.